logo
logo
Sign in

Global Neuralgia Treatment Market Exponential CAGR 6% during forecast period 2021-2028

avatar
Sheryl Dias
Global Neuralgia Treatment Market Exponential CAGR 6% during forecast period 2021-2028

The global neuralgia treatment market was valued at USD 1.8 billion in 2019 and is expanding at a CAGR of 6.0% during the forecast period, 2021-2028. The growth of the market is attributed to increasing number of diabetic patients and high rate of trigeminal neuralgia. Furthermore, conditions such as multiple sclerosis can cause neuralgia. Multiple sclerosis is a condition in which the body’s immune system attacks the myelin sheath, which in turn, causes neuralgia.


Neuralgia is a short, recurring pain in body parts or along a specific nerve. The sensation of pain may feel like stabbing, burning, or an electric shock. The condition is caused, due to the damage to the peripheral nervous system, beyond the brain, and is known as peripheral neuralgia.


Request Free Sample Report Here


Market Trends, Drivers, Restraints, and Opportunities:

  • Increasing number of patients with trigeminal neuralgia is driving the neuralgia treatment market.
  • Rising geriatric population across the world propels the neuralgia treatment market.
  • Increasing number of diabetic patients is anticipated to drive the market.
  • High costs imposed on surgery is hampering the market growth.
  • People belonging to low-income groups cannot afford the neuralgia treatment, as it is expensive. This factor is restraining the market growth.
  • Adverse effects related to the neuralgia treatment and presence of alternative therapies may hamper the neural pain treatment market.
  • Technological advancement leads to new opportunities in the neuralgia treatment market.


Surgery-based Treatment Market held a significant market share

Based on treatment, the neuralgia treatment market is fragmented into drug-based and surgery. The surgery-based treatment segment held the maximum market share in 2019 and is anticipated to grow significantly during the forecast period. The segment is driven by increasing awareness about various treatment options and high cost of surgeries. The surgery segment is sub-segmented into radiofrequency thermal lesioning, stereotactic radiosurgery, Microvascular Decompression (MVD), and others. MVD held a key market share in 2019.

Hospitals and Clinics segment held a key market share in 2019

On the basis of distribution channels, the neuralgia treatment market can be fragmented into hospitals, clinics, retail, and others. The hospitals and clinics segment is expected to dominate the neuralgia treatment market and hold a key revenue share during the forecast period. Increasing cases of neuralgia and rising number of surgical procedures are driving the market. As per the National Institute of Neurological Disorders and Stroke, trigeminal neuralgia is a progressive disorder and often becomes resistant to medication. Hence, the patients usually opt for surgeries.


The ambulatory surgery centers segment is expected to grow rapidly during the forecast period. The growth of the segment is attributed to increasing demand for a reduction in hospital stay. Treatment procedures such as radiofrequency rhizotomy are performed under general anesthesia. This procedure takes a few minutes in the operating room and few additional hours in the recovery room.


North-America dominates the global market

In terms of regions, the neuralgia treatment market is expected to grow rapidly during the forecast period. North America dominated the market and accounted for a revenue share in 2019. The market in North America is anticipated to grow rapidly during the forecast period. Availability of urinary drainage bags market in North America is driven by rising incidence of neuralgia and the presence of key market players in the region. Furthermore, increasing awareness regarding different treatment options is expected to boost the market in North America.


Compititive Landscape

Key players in the neuralgia treatment market include GlaxoSmithKline PLC, Pfizer Inc., Novartis AG, Biogen, Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, Allergan Plc, GlaxoSmithKline Plc., Biogen Inc. and Abbott Laboratories. For instance, in February 2019, Zydus Cadila received FDA approval to market Carbamazepine, which is used in treatment of neuralgia.


About Growth Market Reports:

GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.


Contact:

Growth Market Reports

Phone: +1 909 414 1393

Email: [email protected]

Web: https://growthmarketreports.com

Follow Us: LinkedIn | Twitter

 

 


collect
0
avatar
Sheryl Dias
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more